- Home
- Products
- Customized ADCs
- FUT4
- Anti-FUT4 (Technetium (99mTc) fanolesomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC
Anti-FUT4 (Technetium (99mTc) fanolesomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1177)
This ADC product is comprised of an anti-FUT4 monoclonal antibody conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA. The duocarmycin SA is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, duocarmycin SA binds to DNA, causes DNA damage.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- FUT4
- Alternative Names
- FUT4; fucosyltransferase 4 (alpha (1, 3) fucosyltransferase, myeloid-specific); CD15, ELFT, FCT3A; alpha-(1, 3)-fucosyltransferase; ELAM ligand fucosyltransferase; FUC TIV; galactoside 3 L fucosyltransferase; Lewis X; fucT-IV; fucosyltransferase IV; ELAM-and metabolized via glucuronidation by UGT1A1.
- Target Entrez Gene ID
- 2526
- Target UniProt ID
- P22083
- Overview
- The product of this gene transfers fucose to N-acetyllactosamine polysaccharides to generate fucosylated carbohydrate structures. It catalyzes the synthesis of the non-sialylated antigen, Lewis x (CD15).
- Overview
- Humanized Anti-FUT4 IgM antibody, Technetium (99mTc) fanolesomab
- Generic name
- Technetium (99mTc) fanolesomab
- Host animal
- Mouse
- Name
- MC-Vc-PAB-DMEA-(PEG2)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- duocarmycin SA
- Description
- Duocarmycins SA belong to the minor-groove-binding DNA-alkylating agents (DNA MGBA). The natural duocarmycins are isolated from the culture broth of Streptmyces sp and a series of derivatives has also been synthesized.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CFD (Lampalizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-983)
- Anti-CD22 (Moxetumomab pasudotox)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-804)
- Anti-IL23A (Guselkumab)-MC-MMAF ADC (CAT#: ADC-W-1348)
- Anti-F3 (clone b12)-Mc-MMAF ADC (CAT#: ADC-W-439)
- Anti-TNF (Golimumab)-MC-MMAF ADC (CAT#: ADC-W-1822)
- Anti-MST1R (Narnatumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1601)
- Anti-FGFR2 (clone 12433)-SPDB-DM4 ADC (CAT#: ADC-W-066)
- Anti-CD19 (Blinatumomab)-MC-MMAF ADC (CAT#: ADC-W-778)
- Anti-MIF (Imalumab)-SPDB-DM4 ADC (CAT#: ADC-W-2253)
- Anti-TNFRSF8 (cCA10)-β-glucuronide-doxorubicin propyloxazoline (DPO) ADC (CAT#: ADC-W-353)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1177. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-1172 | Anti-FUT4 (Technetium (99mTc) fanolesomab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2461 | Anti-FUT4 (Fanolesomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2457 | Anti-FUT4 (Fanolesomab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-1175 | Anti-FUT4 (Technetium (99mTc) fanolesomab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-1174 | Anti-FUT4 (Technetium (99mTc) fanolesomab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
CAT# | Product Name | Linker | Payload |
ADC-W-2542 | Anti-CD33 (Gemtuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2559 | Anti-CD79B (Polatuzumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2615 | Anti-MS4A1 (Rituximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2609 | Anti-ITGB3 (Tadocizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2570 | Anti-MUC16 (Sofituzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
CAT# | Product Name | Linker | Payload |
ADC-W-2603 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2619 | Anti-MS4A1-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2609 | Anti-ITGB3 (Tadocizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2570 | Anti-MUC16 (Sofituzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2564 | Anti-MSLN (Anetumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.